Stanford Pre-Clinical Research Evidences CAR-T Cells a Potential Treatment for Pediatric Solid Tumors

May 14, 2019 | Cancer, CAR-T, Oncology, Pediatric Cancer, Stanford

Pediatric Cancer

Healio offers updates on Stanford University School of Medicine research via chimeric antigen receptor T cells targeting B7-H3 and attacking certain solid tumors in several pediatric cancer models.

Stanford’s Robbie G. Majzner, MD said, “The treatment has yet to be tested in humans, but is quickly moving toward clinical trials.” HemOnc Today interviewed Dr. Majzner about this research opportunity. Follow the link to the source for more interesting information on this important topic.

Lead Research/Investigator

Robbie G. Majzner, MD


Pin It on Pinterest